TY  - GEN
AB  - Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
AU  - Chiang, Anne C.,
AU  - Herbst, Roy,
CN  - RC280.L8
DO  - 10.1007/978-3-030-74028-3
DO  - doi
ID  - 1440164
KW  - Lungs
KW  - Lungs
KW  - Poumons
KW  - Poumons
LK  - https://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-74028-3
N1  - Includes index.
N2  - Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
SN  - 9783030740283
SN  - 3030740285
T1  - Lung cancer :new understandings and therapies /
TI  - Lung cancer :new understandings and therapies /
UR  - https://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-74028-3
ER  -